CRISPR Gene Editing Newsletter
Issue #49August 10, 20267 studies
A base editor corrected a dangerous immune mutation with 90% efficiency in patient stem cells
Gene editing just cleared a meaningful bar in immunology: fixing a dominant gain-of-function mutation — the kind where one bad copy of a gene overrides the good one — precisely enough to restore normal immune function.
The tool that did it wasn't CRISPR's scissors. It was a molecular pencil.
A 'Pencil Edit' Fixed a Brutal Immune Disease — No Scissors Required 🧬
- Patients with STAT1 gain-of-function disease face chronic fungal infections, autoimmunity, and elevated cancer risk. The only cure today is a donor stem cell transplant — which carries unusually high complication rates in this specific population.
- Researchers tried standard CRISPR cutting first. It corrected fewer than 25% of cells, hurt viability, and couldn't distinguish the bad gene copy from the good one. Adenine base editing — which chemically rewrites a single DNA letter without cutting the strand — fixed the same mutation in up to 90% of patient T cells and stem cells.
- Edited stem cells held the correction through 16 weeks in mice, maintained the ability to produce multiple blood cell types, and restored measurable immune signaling.
Why it matters: This is the first reported use of gene editing to correct a dominant gain-of-function mutation causing immunodeficiency — a category of genetic disease that cutting-based tools have largely struggled to address.
Key Findings
CRISPR Mapped the Weak Spots in Pancreatic Cancer's Energy Supply ⚡
- A genome-wide CRISPR screen in pancreatic cancer cells identified FGD5 as a protein that stabilizes a key glycolysis enzyme by blocking its degradation — essentially keeping cancer's fuel line open.
- Knocking out FGD5 shifted cells away from sugar-burning toward a less aggressive metabolic mode, and combining a glycolysis blocker with a compound targeting FGD5's stabilization pathway suppressed tumor growth in both lab and animal models.
💡 Pancreatic cancer's metabolic armor has a newly identified chink worth targeting.
Scientists Made Hypoallergenic Dogs. Yes, Really. 🐕
- Using CRISPR-Cas9 and cloning technology, researchers produced two beagle puppies with a frameshift mutation that eliminated Can f 1 — the salivary protein responsible for most dog-specific allergic reactions in sensitized people.
- Saliva and dander from the edited dogs contained no detectable Can f 1, and a skin prick test in a sensitized individual showed no IgE-mediated response to extracts from the edited animals.
💡 Knocking out the main dog allergen at the source is biologically feasible.
A New Lineage-Tracing Tool Records 50x More Cell History 🌳
- BASELINE uses a Cas12a adenine base editor to permanently mark cells as they divide, writing across arrays of 50 synthetic target sites integrated multiple times into the genome — capturing more than 4,300 bits of lineage information per cell in a pancreatic cancer model.
- That's roughly a 50-fold increase in recorded information over existing technologies, with single-cell sequencing capturing an average of 29 cell divisions per lineage.
💡 Mapping how tumors evolve cell by cell just got dramatically more detailed.
An AI-Optimized Gene Integration Tool Didn't Travel Well 🤖
- An AI-guided protein engineering framework nominated a Bxb1 recombinase variant (epBxb1 T166R) as highly active based on plasmid-to-plasmid tests — but when benchmarked in actual human genome contexts, it showed no advantage at one major locus and only modest gains at two others.
- A previously validated variant (eeBxb1) consistently outperformed it by up to 12-fold, and four additional rounds of AI optimization on that scaffold found no reproducible improvement among 40 tested substitutions.
💡 Lab-screen wins don't always survive contact with the actual genome.
256 Patient Tumor Organoids, One Big Gene Dependency Map 🗺️
- Researchers derived 256 tumor organoids from colorectal, pancreatic, ovarian, esophageal, and gastric cancers, then ran genome-wide CRISPR screens across 162 of them to identify which genes each tumor type relies on to survive.
- The dataset revealed genomic markers that predict dependency, organoid-specific essential genes not found in standard cell lines, and differential effects of specific KRAS mutations in colorectal cancer — distinctions that standard lab cell lines had missed.
💡 Patient-derived organoids expose cancer vulnerabilities that cell lines routinely hide.
Hearing Loss Gene Corrected with 58% Efficiency Using Prime Editing 👂
- The GJB2 c.235delC mutation — the most common hereditary hearing loss variant in East Asian populations — was corrected in a cell model using an optimized prime editing approach, reaching 58% efficiency with a nicking strategy and no detectable off-target edits at the top four predicted sites.
- A split delivery system compatible with gene therapy packaging was also developed and showed comparable correction efficiency to a previously validated design.
💡 A common deafness mutation is now correctable at meaningful efficiency without detectable off-target damage.
Implications
Base editing's ability to fix dominant gain-of-function mutations — without cutting DNA — opens a category of genetic disease that standard CRISPR has struggled to touch. The unresolved tension: edited stem cells held their correction in mice for 16 weeks, but whether that durability translates to human immune reconstitution remains untested.
Studies in this issue
Primary sources used for this newsletter.
- Restoring immune function in STAT1 gain-of-function disease using gene-edited stem cellsmain storyBlood2026-08-04PMID 42550765
- Removing the Main Dog Allergen Gene to Reduce Allergieskey findingThe CRISPR journal2026-08-05PMID 42554239
- A collection of tumor-grown mini-organs reveals which cancer genes are needed for growthkey findingNature2026-08-05PMID 42557320
- BASELINE: A gene-editing tool to track individual cell development in mammalskey findingNucleic acids research2026-08-04PMID 42549577
- Precise lab correction of a common GJB2 gene mutation using prime editingkey findingGene therapy2026-08-07PMID 42562992
- AI-Designed Bxb1 Recombinases Work Less Well and Differently Depending on Context in Large-Scale Genome Editingkey findingThe CRISPR journal2026-08-06PMID 42557963
- FGD5 controls PGK1 breakdown to work together with 2-deoxy-D-glucose in pancreatic cancerkey findingOncogene2026-08-07PMID 42567886
Continue reading
All CRISPR Gene Editing issuesGet the next CRISPR Gene Editing issue
Seven papers, once a week. Free.